A 77-year-old man previously treated with maintenance hemodialysis was admitted due to appetite loss, nausea and shortness of breath. He showed progressive heart failure and eosinophilia without any basal disorders and was diagnosed with idiopathic hypereosinophilic syndrome (HES) accompanied by eosinophilic myocarditis. Laboratory data revealed hypercalcemia, a low serum parathyroid hormone level and a high 1,25(OH)2D concentration in spite of renal failure and no causal medications. Steroid therapy resulted in the patient's rapid recovery from heart failure, hypereosinophilia and hypercalcemia. Since the serum 1,25(OH)2D level promptly and markedly decreased, the hypercalcemia complicated with HES was most likely caused by extrarenal production of 1,25(OH)2D.
Introduction
Hypereosinophilic syndrome (HES) is characterized by an increased number of eosinophils in the peripheral blood and tissue in the absence of any known causes of eosinophilia (1) . Eosinophilic myocarditis is a rare disease that is pathologically characterized by diffuse or focal myocardial inflammation with eosinophilic infiltration and is often associated with peripheral blood eosinophilia (2) . Since eosinophilic infiltration occurs in various organs, such as the heart, lungs and intestines, HES develops a wide range of complications. However, hypercalcemia is usually a rare complication of HES. We herein report a case of hypercalcemia caused by active vitamin D associated with eosinophilic myocarditis in a patient undergoing maintenance hemodialysis treatment.
Case Report
A 77-year-old Japanese man had undergone maintenance hemodialysis therapy for eight years due to renal sclerosis and gout. Two months before admission, eosinophilia (1,000/mm 3 ) without any symptoms or causes was found during a regular blood examination. Since the serum calcium concentration was increased, prescriptions for active vitamin D (alfacalcidol 0.25 μg/day) and calcium (CaCO3 3.0 g/day as a phosphate binder) were discontinued. One month later, although no remarkable changes were found in the eosinophil counts, the serum calcium level was found to be further elevated. Since then, the patient sometimes experienced high fever, general fatigue, loss of appetite, nausea, shortness of breath and difficulty falling asleep. He was admitted to our hospital in July 2011 due to deterioration of his symptoms.
On admission, the laboratory data revealed a white blood cell count of 11,740/mm 3 , an eosinophil count of 3,600/mm cytoplasmic-anti-neurophil cytoplasmic antibody, FIP1L1-PDGFR : FIP-like 1 gene to the platelet-derived growth factor receptor *: corrected with serum albumin concentration using Payne's formula (14) tion: 94% (room air); and temperature: 36.8 .
The patient's lymph nodes were not palpable and pitting edema was found bilaterally in the legs. An electrocardiogram (ECG) showed sinus arrhythmia, a poor progression of R waves and depressed ST segments of V5-6. Ultrasound cardiography (UCG) demonstrated diffuse hypokinesis of the left ventricular wall (ejection fraction: 30%), mild pleural effusion and an abnormal relaxation pattern of the transmitral flow velocity. No obvious abnormalities were apparent on chest X-ray or computed tomography images, except for cardiomegaly and pleural effusion. In parallel with the above findings, the serum level of brain natriuretic peptide (BNP) was very high (3,697 pg/mL). Based on these findings, the patient was clinically diagnosed with acute heart failure accompanied by eosinophilic myocarditis. Since the patient's signs and symptoms acutely progressed, we started treatment with prednisolone (30 mg/day) without performing a myocardial biopsy.
The laboratory data regarding calcium metabolism were as follows: serum calcium corrected with albumin: 11.7 mg/ dL; phosphorus: 4.7 mg/dL; intact parathyroid hormone (PTH): 5 pg/mL; PTH-related peptide (PTHrP) below sensitivity; bone-alkaline phosphatase (BAP): 22.0 U/L; and tartrate-resistant acid phosphatase-5b (TRACP-5b): 58 mU/ dL (Table) . Moreover, whole-body bone and gallium scintigraphy were both negative. Interestingly, the level of 1,25(OH)2D was markedly elevated (107 pg/mL) despite the presence of renal failure (Table) . A systemic examination including ophthalmologic and bone-marrow examinations excluded diagnoses of sarcoidosis, tuberculosis, Wegener's granulomatosis and other inflammatory diseases and malignant disorders such as multiple myeloma, metastatic bone tumors and malignant lymphomas, including FIP1 L1-PDGFRα-positive eosionophilic lymphoma.
Prednisolone treatment resulted in the amelioration of the patient's symptoms and a rapid decrease in the eosinophil count (249/mm 3 ) within one week. This was followed by a significant decrease in the BNP level (1,384 pg/mL) and the disappearance of findings of heart failure (EF 46%), pleural effusion and arrhythmia within three weeks (Figure) . Moreover, the levels of 1,25(OH)2D (6 pg/mL) and calcium (8.4 mg/dL) markedly decreased (Figure) .
Discussion
Many diseases, including allergies, lymphomas and inflammatory diseases, can cause HES. This case was diagnosed as idiopathic HES because none of those diseases were observed. Interleukin (IL)-5 induces the production of eosinophils in bone marrow and the migration of eosinophils into the bloodstream. After allergen exposure, mast cells induce the secretion of chemokines and granulocytemacrophage colony-stimulating factor (GM-CSF) via IgE receptors, which results in the activation of eosinophils. Activated eosinophils also activate themselves by secreting IL-5 and GM-CSF (3). In our case, however, the absence of basal diseases, including allergies, and the elevation of the IL-5 level suggest the presence of other unknown mechanisms.
Previous reports have shown that dialysis equipment, including the anti-coagulant and hemodialysis circuits, cause HES through allergic reactions more frequently in patients undergoing hemodialysis than in those undergoing peritoneal dialysis or with non-dialysis kidney disease (4, 5) . However, it is unlikely that hemodialysis was the cause of HES in our case because the dialysis equipment was unchanged and no allergic reactions were observed. On the other hand, an in vitro study has demonstrated that active vitamin D suppresses the production of eosinophils by decreasing the levels of IL-8 (6). Moreover, active vitamin D induces the production of IgE by plasma cells by increasing the rate of Eosinophilic myocarditis is a rare disease that is pathologically characterized by myocardial inflammation with eosinophilic infiltration. Corticosteroid therapy shows great benefits in the treatment of patients with eosinophilic myocarditis (8) . Some patients may be strongly suspected to have a diagnosis of eosinophilic myocarditis without performing a myocardial biopsy (9) . In our case, the patient required immediate therapy due to the progression of acute heart failure. Therefore, we started steroid therapy without performing a myocardial biopsy examination. The patient was strongly suspected to have eosinophilic myocarditis due to the presence of hypereosinophilia, symptoms of heart failure, an increased level of troponin T, changes in the findings of ECG and UCG and the absence of any other disorders that could have explained these findings (9) .
The patient in our case demonstrated a high level of active vitamin D and hypercalcemia despite having end-stage renal failure. Two previous reports have described cases in which both HES and hypercalcemia were observed at the same time (10, 11) . The first case involved a patient with the following laboratory results: eosinophils: 65,250/mm 3 ; serum calcium: 16.4 mg/dL; and intact PTH (the biologically active amino-terminal): 352 pg/mL (normal: 275 to 675 pg/mL). A necropsy performed in that case showed eosinophilic infiltration in the bones, heart, lungs and spleen. Although the levels of bone resorption markers and active vitamin D were not measured, the microscopic findings showed eosinophilic infiltration in the bones and marked bone resorption, most likely leading to hypercalcemia. A low normal range of intact PTH in spite of a reduced renal function and normal findings for the four parathyroid glands on autopsy indicated that the patient did not have primary hyperparathyroidism. The second case involved a patient with the following laboratory values: eosinophils: 14% (unknown absolute count); serum calcium: 12.9 mg/dL; intact PTH below sensitivity; 1,25(OH)2D: 6 pg/mL; ESR: 50 mm/hr; and aldorase: 21 U/L. The patient was diagnosed with eosinophilic fasciitis based on the results of a biopsy of the forearm. The authors reported that local inflammatory cytokines such as IL-1, tumor necrosis factor (TNF) and IL-5 can cause hypercalcemia and eosinophilia, although these data were not shown. While both of these two cases involved hypercalcemia and eosinophilia, active vitamin D was not the cause of hypercalcemia in either case.
In our case, the hypercalcemia has not been caused by either eosinophilic infiltration or local inflammation, as evidenced by the low levels of bone resorption markers and the negative findings on bone scintigraphy. Although the details of the underlying mechanisms are unclear, eosinophiliainduced cytokines may activate 25-hydroxycholecalciferol 1-hydroxylase in macrophages, thus leading to high levels of active vitamin D. As for PTH, the patient in our case had relatively low levels of intact PTH before exacerbation and after demonstrating an improvement of hypercalcemia. Previous reports have shown that high levels of glucose impair PTH section and diabetic patients have lower PTH levels than non-diabetic patients (12, 13) . In this case, although the plasma glucose level had been moderately controlled in recent years, the patient still had diabetes, which might have explained the relatively low PTH levels.
In conclusion, we herein presented a case of hypercalcemia caused by active vitamin D associated with eosinophilic myocarditis in a patient undergoing maintenance hemodialysis. HES patients develop various complications, including hypercalcemia. Our case suggests that active vitamin D may be a cause of hypercalcemia in patients with HES and that glucocorticoid treatment is effective for treating both eosinophilia and hypercalcemia.
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